-
In 2029, the out-of-hospital market will reach 160 million yuan, but the "card slot" of pharmaceutical companies is not easy
Time of Update: 2022-12-30
In recent years, not only multinational pharmaceutical companies, including Guangzhou Medicine Baiyunshan, Harbin Pharmaceutical, Xi'an Janssen, Yiling, Buchang, Jiangsu Wanbang, Besunyen and other local pharmaceutical companies have successively cooperated with emerging industry platforms.
-
Lilly Cardiometabolic New Drug Domestic Clinical, Qilu, Novartis, Sanofi... RNAi therapy involved in the country
Time of Update: 2022-10-03
From: CDE website Dicerna and Eli Lilly have reached a collaboration on 2 RNAi therapies into the clinical phase LY3819469 is a new drug under development for cardiometabolic that has been approved by the FDA in May 2021 and is currently conducting a Phase I clinical study of cardiometabolic diseases (registration number: NCT04914546).
-
Shanghai Pharmaceutical strengthens innovation and research and development to promote the high-quality development of the biomedical industry
Time of Update: 2022-09-30
Recently, when Shanghai Pharmaceutical was surveyed by investors, it said that the company's clinical applications have been accepted and entered the clinical research stage of the new drug pipeline
-
This multinational pharmaceutical company will lay off more than 1,000 employees! A large number of executives are also on the list
Time of Update: 2022-09-09
In addition to Novartis, a large number of multinational pharmaceutical companies have reported layoffs or even delisting during the year.
In addition to Novartis, a large number of multinational pharmaceutical companies have reported layoffs or even delisting during the year.
-
【Visitor Registration】API China 86th China International Pharmaceutical Equipment Exhibition
Time of Update: 2022-05-06
【Visitor Registration】API China 86th China International Pharmaceutical Equipment Exhibition As a professional platform for learning, communication and cooperation in China's pharmaceutical equipment industry, SINOPHEX has always paid attention to green production, continuous flow production, intelligent manufacturing and other industry hotspots.
-
Pay attention to the fast-growing sector in the first quarterly report. Yesterday, many pharmaceutical companies disclosed that their performance increased by more than double
Time of Update: 2022-04-18
According to the forecast, Canaan Technology expects that the net profit attributable to the first quarter of 2022 will increase by 50% to 80% year-on-year, about 16.
-
Competing for the market, domestic pharmaceutical equipment still needs to make efforts in three aspects
Time of Update: 2022-04-03
Industry insiders believe that this is mainly related to factors such as the lack of core technology of pharmaceutical equipment companies, the shortage of R&D funds due to the small scale of the company, and the shortage of professional talents.
-
To release the pressure of reform of pharmaceutical companies, the innovation and upgrading of pharmaceutical equipment cannot be ignored
Time of Update: 2022-03-23
Chemical machinery and equipment network market analysis chemical machinery and equipment In this regard, some people in the pharmaceutical industry have publicly stated, “It is conservatively estimated that in the next few years, under the general trend of medical reform, one-third of domestic pharmaceutical companies will be eliminated.
-
Domestic pharmaceutical companies have set off a "financing fever", and the development of the pharmaceutical and biological industry is being accelerated
Time of Update: 2021-12-30
According to incomplete statistics, the number of IPO pharmaceutical companies on the Science and Technology Innovation Board in the first half of the year has reached 23, with a total financing amount of over 18 billion yuan .
-
With nearly $5 billion smashed in two months, can Pfizer's oncology business break through
Time of Update: 2021-09-10
Accumulated investment of more than 10 billion US dollars betting on oncology business It is understood that Trillium’s main products are two SIRPα-Fc fusion proteins TTI-622 and TTI-621, currently in clinical phase 1b/2, targeting the CD-47-SIRPα pathway, mainly suitable for hematological malignancies .
-
Hainan Boao Lecheng: Promote system integration and innovation to promote the return of overseas medical consumption
Time of Update: 2021-04-14
The State Council approved the establishment of the Hainan Boao Lecheng International Medical Tourism Pilot Zone in 2013, granting it nine preferential policies for importing and using new drugs, medical equipment and equipment that have not been registered and approved in the country.
-
In 2021, 10 patents for the original drug will expire, involving Pfizer, Roche and AbbVie! In 2021, 10 patents for the original drug will expire, involving Pfizer, Roche and AbbVie
Time of Update: 2021-03-21
05px;font-size:16px;text-align:center;"> com" style="margin:0px;padding:0px;color:#333333;"> 25px;font-size:15px;margin-top:20px ;'>E，2021，10，，，。 25px;font-size:15px;margin-top:20px ;'>，10，3，，Vascepa。 5px;background:#3B5CF4;">“” 25px;font-size:15px;margin-top:20px ;'>，，、，，。 25px;font-size:15px;margin-top:20px ;'>，，。25px;font-size:15px;caret-color:red;margin-top:20px ;'>，，。，。 25px;font-size:15px;margin-top:20px ;'>As a result, some pharmaceutical companies began to focus on the field of first generic drugs.
-
In 2017, the market size of Chinese medicine tablets will reach 233 billion
Time of Update: 2021-02-09
In recent years, China's Chinese medicine tablet industry has developed rapidly, with the market size increasing from 85.37 billion yuan in 2011 to 195.6 billion yuan in 2016, with a compound annual growth rate of 19%, leading the pharmaceutical industry in all sectors.
-
Chinese medicine enterprises accelerate the layout transformation of bio-innovative pharmaceutical investment focus
Time of Update: 2021-02-09
According to the Securities Daily reporter combed, including Jiuzhitang, Step Pharmaceuticals, Yunnan White Medicine, Tianshili and other large-scale Chinese medicine enterprises are in the layout of bio-innovative medicine field.
-
From "buy, buy" to "sell", pharmaceutical companies are accelerating their focus on the main business
Time of Update: 2020-11-19
similarly, in its previously disclosed 2020 half-yearly report, Tiansli also showed that, in order to meet the strategic development needs of listed companies and enhance the sustainable development capabilities and core competitiveness of listed companies, on June 12, Tiansli and six partners indirectly controlled by Tiansli sold its stake in Tianjin Tiansli Pharmaceutical Marketing Group Co., Ltd.
